Seattle's Immune Design teams up with Merck, stock soars

Seattle biotech company Immune Design (Nasdaq: IMDZ) announced a new partnership Monday that will help further the company's immunotherapy treatments. Immune Design has entered into a clinical collaboration with New Jersey-based pharmaceutical company Merck (NYSE: MRK) to evaluate the safety and efficacy of two of the Seattle company's immunotherapy products in Phase 1 clinical trails for patients with non-Hodgkin's lymphoma and melanoma. The trials will examine how each of those two products —…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news